Resolution Chemicals Ltd v H. Lundbeck A/S [2013] EWHC 739 (Pat) (12 April 2013)

Resolution Chemicals Ltd v H. Lundbeck A/S [2013] EWHC 739 (Pat) (12 April 2013)

Resolution Chemicals is not precluded from challenging the validity of SPC/GB02/049 for escitalopram. There is no sufficient privity of interest between Resolution and Arrow Generics or Teva entities to bind Resolution by previous litigation outcomes. Resolution was independently managed, had no legal or commercial interest sufficient for privity, and did not participate in or direct prior litigation. Estoppel and abuse of process do not apply.

Citation
[2013] EWHC 739 (Pat)
Parties
Claimant: Resolution Chemicals Limited; Defendant: H. Lundbeck A/S
Jurisdiction
England and Wales
Judgment Date
12 April 2013
Procedural Posture
Patent Revocation and Summary Judgment Applications / Judgment on Preliminary Issue and Summary Judgment Applications
Outcome
Lundbeck's application for summary judgment on estoppel/abuse of process grounds dismissed; Resolution not precluded from bringing claim.
Legal Topics
Patent Validity, Supplementary Protection Certificates, Estoppel, Abuse of Process, Privity of Interest, Summary Judgment
Intellectual Property Pharmaceutical Law Civil Procedure Patent Validity Supplementary Protection Certificates Estoppel Abuse of Process Privity of Interest +1 more

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 4 Authorities cited 16 Party arguments 2 Amounts and remedies 2
Sign in to unlock

Parties

Resolution Chemicals Limited

Claimant

H. Lundbeck A/S

Defendant

Procedural Posture

Patent Revocation and Summary Judgment Applications / Judgment on Preliminary Issue and Summary Judgment Applications

Legal Issues

  1. 1 Is Resolution Chemicals precluded from challenging the validity of SPC/GB02/049 for escitalopram by reason of cause of action estoppel, issue estoppel, or abuse of process?
  2. 2 Does privity of interest exist between Resolution Chemicals and Arrow Generics or Teva entities such that Resolution is bound by previous litigation outcomes?
  3. 3 Does Resolution's claim for revocation of the SPC have a real prospect of success given prior UK and foreign litigation upholding the patent?

Ratio Decidendi

Resolution Chemicals is not precluded from challenging the validity of SPC/GB02/049 for escitalopram. There is no sufficient privity of interest between Resolution and Arrow Generics or Teva entities to bind Resolution by previous litigation outcomes. Resolution was independently managed, had no legal or commercial interest sufficient for privity, and did not participate in or direct prior litigation. Estoppel and abuse of process do not apply.

Court Disposition

Lundbeck's application for summary judgment on estoppel/abuse of process grounds dismissed; Resolution not precluded from bringing claim.

Orders

  • Resolution permitted to proceed with claim for revocation of SPC/GB02/049.
  • Applications for summary judgment on merits and permission to amend grounds stood over for further hearing.